Literature DB >> 3292144

Blood pressure changes during treatment with recombinant human erythropoietin.

W Samtleben1, C A Baldamus, J Bommer, W Fassbinder, B Nonnast-Daniel, H J Gurland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3292144     DOI： 10.1159/000416009

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  7 in total

1.  Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.

Authors:  C G Winearls
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

2.  [Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia--a possible cause of increased blood pressure in relation to recombinant human erythropoietin?].

Authors:  R Müller; H M Steffen; R Brunner; M Pollok; C A Baldamus; W Kaufmann
Journal:  Klin Wochenschr       Date:  1991-10-18

Review 3.  Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Authors:  Farhanah Yousaf; Bruce Spinowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 4.  [Erythropoietin and hypertension].

Authors:  U Frei; B Nonnast-Daniel; K M Koch
Journal:  Klin Wochenschr       Date:  1988-09-15

5.  Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension.

Authors:  I Sasagawa; T Nakada; T Hashimoto; Y Kubota; H Suzuki; T Sawamura
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 6.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

7.  Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties.

Authors:  Ismayil Ahmet; Edward G Lakatta; Mark I Talan
Journal:  Biol Open       Date:  2012-08-22       Impact factor: 2.422
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.